This finding indicated that targeting tumor-associated pDCs to restore their IFN-α production may be a promising strategy, achieved by combining TLR-7/9-based immunotherapy with TGF-β and TNF-α antagonists, in breast cancer (67). This evidence concerns the gene TLR7 and neoplasm.